|

ANIKA THERAPEUTICS INC (ANIK)

US0352551081 - Common Stock

22.46  -0.02 (-0.09%)

After market: 22.46 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028
Revenue
YoY % growth
130.5M
13.87%		147.8M
13.26%		156.2M
5.68%		168.4M
7.81%
EBITDA
YoY % growth
27.66M
-31.18%		16.92M
-38.83%		-4.92M
-129.08%		7.013M
242.54%
EBIT
YoY % growth
14.2M
-58.48%		2.6M
-81.69%		-19.4M
-846.15%		-29.581M
-52.48%		N/AN/AN/A
Operating Margin
10.88%1.76%-12.42%-17.57%N/AN/AN/A
EPS
YoY % growth
-0.64
-131.07%		0.29
145.31%		-0.89
-406.90%		-1.64
-83.75%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.27
21.00%
Revenue
Q2Q % growth		42.231M
6.59%
EBITDA
Q2Q % growth		2.297M
EBIT
Q2Q % growth		-5.504M
17.48%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth		 -0.45
-200.00%		-0.38-0.07-18.17%
Q2 2023
Q2Q % growth		 -0.19
5.00%		-0.280.0931.01%
Q1 2023
Q2Q % growth		 -0.47
-135.00%		-0.31-0.16-53.59%
Q4 2022
Q2Q % growth		 -0.34
15.00%		-0.24-0.10-38.89%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth		 41.47M
3.01%		39.031M2.439M6.25%
Q2 2023
Q2Q % growth		 44.3M
11.70%		41.368M2.932M7.09%
Q1 2023
Q2Q % growth		 37.92M
3.35%		38.026M-106K-0.28%
Q4 2022
Q2Q % growth		 39.62M
10.61%		38.459M1.161M3.02%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 12.22% -2.34% -452.87%
Revenue0% 1.43% 2.36% 2.01%